Tyra Biosciences, Inc. (TYRA)

NASDAQ • Healthcare

$20.45

-$0.42 (-2.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$20.85

Previous Close$20.45

Day Range$20.09 - $20.85

Avg. Volume (3M)675K

Market Cap$1.2B

52 Week Range

$13.35$40.65

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$148.5M

EPS (TTM)

-$2.4

ROA (TTM)

-38.75%

Current Ratio

14.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+11.3%Q3 2025-$0.47

0.0%Q4 2025-$0.5

-5.6%Q1 2026-$0.57

-6.7%Q2 2026-$0.64

-6.2%Q3 2026-$0.69

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -6.2%

Tyra Biosciences’ EPS trailed expectations in the second fiscal quarter of 2026, with results reported August 4, 2026 based on preliminary figures, as EPS came in at -$0.69 versus the -$0.65 estimate (difference -$0.04). Net income was a loss of roughly $45.6 million, down -62.1% year over year from a loss of about $28.1 million, while EPS declined -46.8% from -$0.47 a year ago. The company posted an operating loss of about $49.0 million as it continues development work in targeted oncology programs such as TYRA-300, and it generated negative operating cash flow of roughly $31.1 million during the quarter. For the next period, consensus calls for EPS of -$0.69.

Next report — what to expect

Tyra Biosciences, Inc. (TYRA) reports next on November 4, 2026. Wall Street’s consensus calls for EPS of -$0.66. The main watch item is any updates that clarify the company’s financial trajectory alongside the headline EPS, after it has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops targeted cancer medicines. Trading as TYRA, the company is a small-cap drug developer built around precision therapies for oncology, with work centered on overcoming tumor resistance rather than on a marketed product base.

Name

Tyra Biosciences, Inc.

CEO

Todd Harris

Website

www.tyra.bio

Industry

Healthcare

Year Founded

2018

Employees

Today's Snapshot

AI-generated

TYRA closed 2% below yesterday's close, in line with a weaker sector. TYRA reports earnings on 4 November.

Trading Volume

Below 10d avg (583.3K)

514.3K

vs S&P 500 Today

Underperforming Market

-1.49%

Updated: October 23, 2026 at 20:09 UTC

Technical Indicators

1 Buy3 Neutral4 Sell

TYRA presents a mixed short-term tone but a clearly negative longer-term structure, with the price below most medium and long moving averages and well under the 50–200 day levels, which weighs on the outlook. Momentum readings are muted and MACD is negative, while ADX near 20 denotes limited trend conviction; paradoxically OBV shows recent accumulation but it has not translated into breakout strength. Elevated ATR around 5.7 percent points to higher volatility, increasing downside risk while trend alignment remains unfavorable. Technical takeaway: Sell.

All signals